Jenscare Scientific (HKG:9877) said the success rate for its LuX-Valve Plus transcatheter tricuspid valve replacement device, tested during a 30-day global follow-up study, reached 97%, according to a Friday filing with the Hong Kong bourse.
The study, performed on 161 patients in 20 centers worldwide, also showed good safety and performance of the device, the filing said.
Meanwhile, Jenscare's JensClip transcatheter mitral valve repair system showed a device operation success rate of 95% during its one-year follow-up study in China, the filing said.
Jenscare performed the study on 114 patients with an average age of 71 years across 18 centers in China.
Jenscare presented the results of the 30-day study during the EuroPCR 2025 in Paris.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。